TRMT10B

Across TCGA pan-cancer cohorts, TRMT10B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRMT10B data layer compared with 29 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher TRMT10B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRMT10B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, UCEC, and LIHC are the cancer types where TRMT10B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.261	0.798	.006	12	view →
UCEC	DFS	Median	II,III,IV	0.918	0.437	.027	10	view →
LIHC	OS	Median	III,IV	0.270	0.732	.021	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TRMT10B–CESC (OS)

Open the CESC breakdown →